Next-generation pediatric care: nanotechnology-based and AI-driven solutions for cardiovascular, respiratory, and gastrointestinal disorders

被引：1

作者：

Lima, Waldenice de Alencar Morais ^{[1
]}

de Souza, Jackson G. ^{[2
]}

Garcia-Villen, Fatima ^{[3
]}

Loureiro, Julia Lira ^{[1
]}

Raffin, Fernanda Nervo ^{[1
]}

Fernandes, Marcelo A. C. ^{[2
,4
]}

Souto, Eliana B. ^{[5
]}

Severino, Patricia ^{[6
]}

Barbosa, Raquel de M. ^{[7
]}

机构：

[1] Univ Fed Rio Grande do Norte, Dept Pharm, Lab Galen Pharm, BR-59012570 Natal, Brazil

[2] Univ Fed Rio Grande do Norte, InovAI Lab, nPITI IMD, BR-59078970 Natal, RN, Brazil

[3] Univ Granada, Sch Pharm, Dept Pharm & Pharmaceut Technol, Campus Cartuja, Granada 18071, Spain

[4] Univ Fed Rio Grande do Norte, Dept Comp Engn & Automat, BR-59078970 Natal, RN, Brazil

[5] Univ Porto, Fac Pharm, Lab Pharmaceut Technol, Rua Jorge de Viterbo Ferreira 228, P-4050313 Porto, Portugal

[6] Univ Tiradentes UNIT, Ind Biotechnol Program, BR-49032490 Aracaju, Sergipe, Brazil

[7] Univ Seville, Sch Pharm, Dept Pharm & Pharmaceut Technol, C Prof Garcia Gonzalez 2, Seville 41012, Spain

来源：

WORLD JOURNAL OF PEDIATRICS | 2025年 / 21卷 / 01期

关键词：

Artificial intelligence; Conventional therapy; Nanotechnology; Pediatrics; Theragnostics; TARGET INTERACTION PREDICTION; LABEL DRUG-USE; IN-VITRO; DELIVERY; NANOPARTICLES; CHILDREN; NANOTHERANOSTICS; CHALLENGES; THERAPY; STRATEGIES;

D O I：

10.1007/s12519-024-00834-x

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

BackgroundGlobal pediatric healthcare reveals significant morbidity and mortality rates linked to respiratory, cardiac, and gastrointestinal disorders in children and newborns, mostly due to the complexity of therapeutic management in pediatrics and neonatology, owing to the lack of suitable dosage forms for these patients, often rendering them "therapeutic orphans". The development and application of pediatric drug formulations encounter numerous challenges, including physiological heterogeneity within age groups, limited profitability for the pharmaceutical industry, and ethical and clinical constraints. Many drugs are used unlicensed or off-label, posing a high risk of toxicity and reduced efficacy. Despite these circumstances, some regulatory changes are being performed, thus thrusting research innovation in this field.Data sourcesUp-to-date peer-reviewed journal articles, books, government and institutional reports, data repositories and databases were used as main data sources.ResultsAmong the main strategies proposed to address the current pediatric care situation, nanotechnology is specially promising for pediatric respiratory diseases since they offer a non-invasive, versatile, tunable, site-specific drug release. Tissue engineering is in the spotlight as strategy to address pediatric cardiac diseases, together with theragnostic systems. The integration of nanotechnology and theragnostic stands poised to refine and propel nanomedicine approaches, ushering in an era of innovative and personalized drug delivery for pediatric patients. Finally, the intersection of drug repurposing and artificial intelligence tools in pediatric healthcare holds great potential. This promises not only to enhance efficiency in drug development in general, but also in the pediatric field, hopefully boosting clinical trials for this population.ConclusionsDespite the long road ahead, the deepening of nanotechnology, the evolution of tissue engineering, and the combination of traditional techniques with artificial intelligence are the most recently reported strategies in the specific field of pediatric therapeutics.

引用

页码：8 / 28

页数：21